News

Medix

Medix Biochemica expands its monoclonal antibody offering through the acquisition of Diaclone

Publication date : 2021-07-13

Press Release - 13 July 2021

 

Medix Biochemica expands its monoclonal antibody offering through the acquisition of Diaclone

  • Medix Biochemica has acquired 100 percent of the shares of Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology and immunology.
  • The acquisition expands Medix Biochemica’s leading portfolio of IVD raw materials, bringing complementary scientific and technological capabilities and strengthening the company’s local presence in Western Europe.
  • As a result of the transaction, Diaclone’s product portfolio will be available through Medix Biochemica’s comprehensive global sales network.

Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of Diaclone SAS (“Diaclone”) from Biotech Investissement Group. As a result of the acquisition, Medix Biochemica broadens its portfolio of critical raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its local presence in Western Europe. Diaclone will become an important part of the Immunodiagnostic Reagents Business Unit within Medix Biochemica’s group structure, and its high-quality operations will continue in Besançon, France.

Founded in 1986, Diaclone is widely recognized for its expertise in the fields of inflammation, oncology and immunology. The company offers best-in-class monoclonal antibodies, high quality ELISA and ELISpot kits as well as custom services - ranging from immunoassay kit development to new antibody discovery using hybridoma and phage display technologies - to a broad range of IVD, life science, and pharma customers. Diaclone employs a team of ca. 25 professionals in Besançon, France.

“The acquisition of Diaclone is an important step towards our vision to be the first-choice, independent raw material partner for the IVD industry. The portfolio of Diaclone, including several gold standard antibodies, complements the offering of Medix Biochemica very well, and we are excited about the opportunity to offer these products to our global customer base. In addition, we see an excellent strategic and cultural fit with Medix Biochemica, and we value Diaclone’s technical and scientific competence highly. We look forward to jointly developing innovative and high-quality products to support our customers even better in the future”, says Steve Ferguson, CEO of Medix Biochemica.

“Following careful consideration, we concluded that it is the right time to find a new partner to support Diaclone’s future international growth. We are convinced that Medix Biochemica with its comprehensive reach to IVD customers globally, strong focus on quality and R&D and clear long-term vision, is the optimal new partner for Diaclone”, says Philippe Dulieu, President of Biotech Investissement Group.

 

More information

Steve Ferguson, CEO of Medix Biochemica

Phone: +358 9 547 680

Email: steve.ferguson@medixbiochemica.com

 

Medix Biochemica

Medix Biochemica Group are a global, market-leading supplier of critical raw materials to the in vitro diagnostics (IVD) industry. Our mission is to enable IVD customers to deliver accurate results to billions of patients worldwide. By working in partnership with Medix Biochemica, IVD manufacturers can reduce their time to market through our industry-leading expertise which increases efficiencies and builds quality into their tests. We achieve this through our deep scientific know-how combined with the broadest and most relevant raw material portfolio and our relentless focus on quality.

Medix Biochemica Group employs more than 200 professionals worldwide. With headquarters in Finland, we serve our worldwide customers through our local teams in the US, Europe, and Asia. www.medixbiochemica.com

 

 

 

 

 

Other news

  • New Diaclone Catalogue!
    New Diaclone Catalogue available
    Publication date : 2021-10-14
    Click and discover what's new... Read more
  • Medica
    Medica 2021 exhibition is coming up
    Publication date : 2021-10-14
    We'll be happy to meet you there! Read more
  • Variant
    Now available - SARS-CoV-2 Spike RBD Variant Delta
    Publication date : 2021-07-27
    Developed in our laboratories in Besançon (France) #715-H25-0BU SARS-CoV-2 Spike RBD Variant Delta Lineage B.1.617.2 Read more
  • ELISPOT
    Diaclone ELISpot assays, tried and trusted by researchers worldwide
    Publication date : 2021-04-01
    Our BEST SELLER the IFNγ ELISpot assay, is widely used in clinical cancer studies and also in COVID-19 research Read more
  • ELISPOT man
    ELISpot Kits - A new format to meet your demands
    Publication date : 2021-02-25
    The Diaclone ELISpot kit range is extended with a new 2 PLATE FORMAT Read more
  • Seed machine
    Monoclonal Antibody Platform
    Publication date : 2021-02-05
    Diaclone and Seed Biosciences collaborate on the development of a new workflow for a faster and more efficient antibody development process Read more
  • Covid rec proteins
    NEW!... RECOMBINANT HUMAN SARS-CoV-2 PROTEINS
    Publication date : 2020-10-15
    Developed in our laboratories in Besançon (France) Read more
  • Spike Protein
    Anti-S1 Domain Spike Protein is now available at Diaclone
    Publication date : 2020-08-03
    Ideal for your COVID-19 studies... Read more
  • IL1RAP
    IL1RAP, a therapeutic target for oncologic treatment
    Publication date : 2020-08-03
    Discover our new IL1RAP clones... Read more
  • Exosomes
    What you need to know about Exosomes
    Publication date : 2020-07-01
    “Huge opportunities”. “Many hurdles”. “Enormous potential”.... Read more
  • cytokines
    Fast track your Covid-19 Research with Diaclone’s CYTOKINES
    Publication date : 2020-05-18
    Essential tools for Cytokine Storm monitoring & Immunotherapy development... Read more
  • Virus
    Essential tools for COVID-19 and Immunotherapy research
    Publication date : 2020-04-02
    Diaclone provides a large panel of research tools, Monoclonal Antibodies and Immunoassays, for measuring the levels of released cytokines triggered by viral infection (cytokine release syndrome - CRS), including a complete range of human IL-6 and TNF-α products. Read more
  • Corona
    Human IL-6 cytokine, a useful tool for Coronavirus disease (COVID-19) and Immunotherapy research
    Publication date : 2020-03-20
    DIACLONE provides a large panel of products for the quantification of human IL-6 and other human cytokines. Read more
  • Diaclone's Toolbox
    Use Diaclone’s Toolbox to monitor your CAR-T cell responses
    Publication date : 2019-12-16
    In vitro studies with Diaclone’s Toolbox to monitor the risks linked to immunotherapy.... Read more
  • Toolbox
    Diaclone's Toolbox for your Car-T Development
    Publication date : 2019-11-12
    Our Monoclonal Antibodies and ELISpot range are valuable tools for your CAR-T research. Read more
  • CAR-T development
    CAR-T development
    Publication date : 2019-10-01
    How can Diaclone support your CAR-T development? Read more
  • Diaclone est partenaire d’un projet européen d’envergure associant une douzaine de partenaires de la région de Besançon.
    MiMédi Project
    Publication date : 2019-08-29
    Diaclone is a partner in a major European project involving a dozen partners from the Besançon region. Read more
  • Assays for the Human IL-17 Family
    DIACLONE Assays for the Human IL-17 Family
    Publication date : 2019-08-28
    Diaclone has developed a large range of ELISA and ELISpot kits for the detection of Human IL-17A, IL-17F and IL-17A/F. Read more
  • DIACLONE
    The CAM family: A new target for monitoring or treating cancers?
    Publication date : 2019-08-28
    The cell adhesion molecules (CAMs) family includes more than 50 proteins with four main groups: immunoglobulin (Ig)-like CAMs, cadherins, selectins, and integrins. Read more

Product search